PAN 5 (Pancrelipase delayed-release 16,000 units amylase / 3,000 USP units lipase / 10,000 USP units protease)
Pill imprint PAN 5 has been identified as Pancrelipase delayed-release 16,000 units amylase / 3,000 USP units lipase / 10,000 USP units protease.
Pancrelipase is used in the treatment of chronic pancreatitis; pancreatic exocrine dysfunction; cystic fibrosis and belongs to the drug class digestive enzymes. Risk cannot be ruled out during pregnancy. Pancrelipase 16,000 units amylase / 3,000 USP units lipase / 10,000 USP units protease is not a controlled substance under the Controlled Substance Act (CSA).
- PAN 5
- 16,000 units amylase / 3,000 USP units lipase / 10,000 USP units protease
- Rx and/or OTC
- Drug Class:
- Digestive enzymes
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- X-GEN Pharmaceuticals, Inc.
More about pancrelipase
- Amylase/lipase/protease delayed-release capsules
- Pancrelipase capsules
- Pancrelipase capsules (enteric-coated)
- More (3) »
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.